A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y 12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention | Zendy

Robert C. Welsh | Zendy; Sunil V. Rao | Zendy; Uwe Zeymer | Zendy; Vivian P. Thompson | Zendy; Kurt Huber | Zendy; Janusz Kochman | Zendy; Matthew W. McClure | Zendy; Daniel D. Gretler | Zendy; Deepak L. Bhatt | Zendy; C. Michael Gibson | Zendy; Dominick J. Angiolillo | Zendy; Paul A. Gurbel | Zendy; Lisa G. Berdan | Zendy; Gayle Paynter | Zendy; Sergio Leonardi | Zendy; Mina Madan | Zendy; William J. French | Zendy; Robert A. Harrington | Zendy

Open Access

A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y ₁₂ Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention

Author(s) -

Robert C. Welsh,

Sunil V. Rao,

Uwe Zeymer,

Vivian P. Thompson,

Kurt Huber,

Janusz Kochman,

Matthew W. McClure,

Daniel D. Gretler,

Deepak L. Bhatt,

C. Michael Gibson,

Dominick J. Angiolillo,

Paul A. Gurbel,

Lisa G. Berdan,

Gayle Paynter,

Sergio Leonardi,

Mina Madan,

William J. French,

Robert A. Harrington

Publication year - 2012

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.111.964197

Subject(s) - medicine , clopidogrel , percutaneous coronary intervention , myocardial infarction , tolerability , cardiology , clinical endpoint , anesthesia , hazard ratio , randomized controlled trial , confidence interval , adverse effect

We evaluated the safety, efficacy, and tolerability of elinogrel, a competitive, reversible intravenous and oral P2Y(12) inhibitor that does not require metabolic activation, in patients undergoing nonurgent percutaneous coronary intervention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research